Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

66.43 +1.92 (+2.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 598,864
Open 64.90
Bid (Size) 63.19 (1)
Ask (Size) 69.53 (1)
Prev. Close 64.51
Today's Range 63.52 - 67.06
52wk Range 21.06 - 79.65
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
From Prothena Corporation plc
Via Business Wire
Looking Into Prothena Corp's Return On Capital Employed
 
Via Benzinga

Performance

YTD
+24.17%
+24.17%
1 Month
+23.45%
+23.45%
3 Month
+19.14%
+19.14%
6 Month
+14.30%
+14.30%
1 Year
+143.96%
+143.96%

More News

Read More
Recap: Prothena Corp Q1 Earnings
Via Benzinga
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Prothena Corp Earnings Preview
Via Benzinga
Where Prothena Corp Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Prothena Corp
Via Benzinga
Earnings Outlook For Prothena Corp
Via Benzinga
Another Sucess In Alzheimer’s Disease
Via Talk Markets
Prothena to Report First Quarter 2023 Financial Results on May 4
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in 2023 Bank of America Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
From Walgreens
Via Business Wire
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
Via Benzinga
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in Stifel 2023 Virtual CNS Days
From Prothena Corporation plc
Via Business Wire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
Via FinancialNewsMedia
Exposures COVID-19
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
From Prothena Corporation plc
Via Business Wire
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Prothena Corporation plc
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
Earnings Scheduled For February 23, 2023
Via Benzinga
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.